Home

Theratechnologies Inc. - Common Shares (THTX)

1.5500
-0.0300 (-1.90%)

Theratechnologies Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic solutions for patients with unmet medical needs, particularly in the areas of endocrine and metabolic disorders

The company is primarily engaged in creating treatments that target specific conditions related to aging and severe hormonal imbalances, leveraging its expertise in peptide and protein therapeutics. Through its research and development efforts, Theratechnologies aims to improve the quality of life for patients while advancing scientific understanding in its therapeutic areas.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close1.580
Open1.590
Bid1.550
Ask1.610
Day's Range1.530 - 1.590
52 Week Range1.080 - 2.180
Volume137,842
Market Cap119.37M
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume112,979

News & Press Releases

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV
By Theratechnologies · Via GlobeNewswire · March 12, 2025
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
Study Demonstrates Excess Visceral Abdominal Fat Drives CV Risk
By Theratechnologies · Via GlobeNewswire · March 12, 2025
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
MONTREAL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today reported business highlights and financial results for the fourth quarter and full year of fiscal year 2024, ended November 30, 2024. All figures are in U.S. dollars unless otherwise stated.
By Theratechnologies · Via GlobeNewswire · February 26, 2025
Earnings Scheduled For February 26, 2025benzinga.com
Via Benzinga · February 26, 2025
Examining the Future: Theratechnologies's Earnings Outlookbenzinga.com
Via Benzinga · October 9, 2024
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2024 ended November 30 on Wednesday, February 26, 2025, at 8:30 a.m. ET.
By Theratechnologies · Via GlobeNewswire · February 14, 2025
Theratechnologies Resumes Distribution of EGRIFTA SV®
MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced that it has resumed distribution of EGRIFTA SV® (tesamorelin for injection), following correspondence from the U.S. Food and Drug Administration (FDA) that allows the Company to release two recently manufactured batches of EGRIFTA SV®. The product is ready for immediate shipment to network pharmacies.
By Theratechnologies · Via GlobeNewswire · February 13, 2025
Theratechnologies Provides Update on EGRIFTA SV® Supply
MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that a shortage of EGRIFTA SV® (tesamorelin for injection) will occur at the patient level in mid-January 2025, following a voluntary shutdown of the contract manufacturing facility in 2024. While the Company is aware of remaining inventory of EGRIFTA SV® in certain pharmacies throughout the United States, several pharmacies have reported stockouts.
By Theratechnologies · Via GlobeNewswire · January 9, 2025
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
MONTREAL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has submitted a Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration (FDA) describing the changes made to the manufacturing environment of the facility where EGRIFTA SV® is produced. A PAS is reviewed by the FDA within four months of receipt and an approval is needed prior to the distribution of the recently manufactured batches of EGRIFTA SV®.
By Theratechnologies · Via GlobeNewswire · December 18, 2024
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 25, 2025 to the Company’s recently submitted supplemental Biologics License Application for the F8 formulation of tesamorelin.
By Theratechnologies · Via GlobeNewswire · December 10, 2024
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients
By Theratechnologies · Via GlobeNewswire · December 9, 2024
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
Addition of investigational RNA-targeted medicines build upon Theratechnologies’ foundational HIV portfolio
By Theratechnologies · Via GlobeNewswire · December 4, 2024
Theratechnologies Announces Resumed Production of EGRIFTA SV®
MONTREAL, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the production of EGRIFTA SV® has resumed following a voluntary shutdown of the Company’s contract manufacturer’s facility to address observations from an inspection by the US Food and Drug Administration (FDA).
By Theratechnologies · Via GlobeNewswire · December 3, 2024
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
MONTREAL, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed on a $40 million three-year non-dilutive, senior secured syndicated financing with TD Bank, as agent (TD Bank Financing). The new credit facilities include a $20 million accordion feature, which could expand total commitments up to $60 million. Investissement Québec (IQ), the Company’s largest shareholder, has also agreed to provide a $15 million second ranking secured subordinated term loan (IQ Subordinated Loan). Net proceeds from the new loans together with cash on hand will be used to repay all obligations including prepayment penalties under the Company’s existing facility with affiliates of Marathon Asset Management, L.P. (Marathon) pursuant to the credit agreement entered into with Marathon in July 2022, and to fund business development activities. All amounts are in US dollars unless otherwise stated.
By Theratechnologies · Via GlobeNewswire · December 2, 2024
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
Resubmission addresses questions raised in January 2024 Complete Response Letter
By Theratechnologies · Via GlobeNewswire · November 26, 2024
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
Data Show Tesamorelin May Reduce CVD Risk by Reducing EVAF
By Theratechnologies · Via GlobeNewswire · October 17, 2024
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other Regimens
By Theratechnologies · Via GlobeNewswire · October 17, 2024
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
MONTREAL, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2024 ended August 31, 2024 (Q3 2024). All figures are in US dollars unless otherwise stated.
By Theratechnologies · Via GlobeNewswire · October 10, 2024
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today announced three upcoming poster presentations at IDWeek 2024, taking place October 16-19 in Los Angeles, Calif.
By Theratechnologies · Via GlobeNewswire · October 9, 2024
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
MONTREAL, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third quarter ended August 31, 2024, on Thursday, October 10 at 8:30 a.m. ET.
By Theratechnologies · Via GlobeNewswire · September 26, 2024
Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delaysbenzinga.com
Theratechnologies anticipates a temporary supply disruption of Egrifta SV in 2025 due to an FDA-linked manufacturer shutdown, but the company is working to minimize the impact while adjusting revenue projections for 2024.
Via Benzinga · September 19, 2024
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
MONTREAL, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced a risk of a temporary supply disruption for EGRIFTA SV® (tesamorelin for injection) in early 2025 caused by an unexpected voluntary shutdown of the Company’s contract manufacturer’s facility following an inspection by the US Food and Drug Administration (FDA), as well as the FDA review timeline to resume distribution of the product.
By Theratechnologies · Via GlobeNewswire · September 17, 2024
Theratechnologies to Present at Upcoming Investor Conferences in September
MONTREAL, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company’s President and CEO, Paul Lévesque will be presenting at two investor conferences in September. Members of the Theratechnologies management team will also be available for one-on-one meetings throughout the conferences.
By Theratechnologies · Via GlobeNewswire · September 9, 2024
THTX Stock Earnings: Theratechnologies Beats EPS, Beats Revenue for Q2 2024investorplace.com
THTX stock results show that Theratechnologies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · July 10, 2024
HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soarsbenzinga.com
Theratechnologies reports Q2 2024 sales of $22.02 million, a 25.5% YoY increase, driven by strong demand for EGRIFTA SV. Net income reached $1 million with an adjusted EBITDA of $5.5 million. The company expects FY 2024 revenue of $87-$90 million and adjusted EBITDA of $13-$15 million.
Via Benzinga · July 10, 2024